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Eﬀ ect of radiotherapy after mastectomy and axillary surgery 
on 10-year recurrence and 20-year breast cancer mortality: 
meta-analysis of individual patient data for 8135 women in 
22 randomised trials
EBCTCG (Early Breast Cancer Trialists’ Collaborative Group)*
Summary
Background Postmastectomy radiotherapy was shown in previous meta-analyses to reduce the risks of both recurrence 
and breast cancer mortality in all women with node-positive disease considered together. However, the beneﬁ t in 
women with only one to three positive lymph nodes is uncertain. We aimed to assess the eﬀ ect of radiotherapy in 
these women after mastectomy and axillary dissection.
Methods We did a meta-analysis of individual data for 8135 women randomly assigned to treatment groups during 
1964–86 in 22 trials of radiotherapy to the chest wall and regional lymph nodes after mastectomy and axillary surgery 
versus the same surgery but no radiotherapy. Follow-up lasted 10 years for recurrence and to Jan 1, 2009, for mortality. 
Analyses were stratiﬁ ed by trial, individual follow-up year, age at entry, and pathological nodal status.
Findings 3786 women had axillary dissection to at least level II and had zero, one to three, or four or more positive nodes. 
All were in trials in which radiotherapy included the chest wall, supraclavicular or axillary fossa (or both), and internal 
mammary chain. For 700 women with axillary dissection and no positive nodes, radiotherapy had no signiﬁ cant eﬀ ect on 
locoregional recurrence (two-sided signiﬁ cance level [2p]>0·1), overall recurrence (rate ratio [RR], irradiated vs not, 1·06, 
95% CI 0·76–1·48, 2p>0·1), or breast cancer mortality (RR 1·18, 95% CI 0·89–1·55, 2p>0·1). For 1314 women with 
axillary dissection and one to three positive nodes, radiotherapy reduced locoregional recurrence (2p<0·00001), overall 
recurrence (RR 0·68, 95% CI 0·57–0·82, 2p=0·00006), and breast cancer mortality (RR 0·80, 95% CI 0·67–0·95, 
2p=0·01). 1133 of these 1314 women were in trials in which systemic therapy (cyclophosphamide, methotrexate, and 
ﬂ uorouracil, or tamoxifen) was given in both trial groups and, for them, radiotherapy again reduced locoregional 
recurrence (2p<0·00001), overall recurrence (RR 0·67, 95% CI 0·55–0·82, 2p=0·00009), and breast cancer mortality 
(RR 0·78, 95% CI 0·64–0·94, 2p=0·01). For 1772 women with axillary dissection and four or more positive nodes, 
radiotherapy reduced locoregional recurrence (2p<0·00001), overall recurrence (RR 0·79, 95% CI 0·69–0·90, 2p=0·0003), 
and breast cancer mortality (RR 0·87, 95% CI 0·77–0·99, 2p=0·04).
Interpretation After mastectomy and axillary dissection, radiotherapy reduced both recurrence and breast cancer 
mortality in the women with one to three positive lymph nodes in these trials even when systemic therapy was given. 
For today’s women, who in many countries are at lower risk of recurrence, absolute gains might be smaller but 
proportional gains might be larger because of more eﬀ ective radiotherapy.
Funding Cancer Research UK, British Heart Foundation, UK Medical Research Council.
Copyright © EBCTCG. Open Access article distributed under the terms of CC BY.
Introduction
For many women with early-stage breast cancer, 
mastectomy can remove any detectable macroscopic 
disease, but some tumour foci might remain in 
locoregional tissue (ie, chest wall or regional lymph 
nodes) that could, if untreated, lead to recurrence of the 
disease and death from breast cancer. Radiotherapy has 
the potential to eliminate such tumour foci, and 
guidelines1–6 now recommend that postmastectomy 
radiotherapy be given for women with four or more 
positive axillary lymph nodes, but not given for most 
women with node-negative disease. Most of these 
guidelines conclude, however, that there is insuﬃ  cient 
evidence to make ﬁ rm recommendations for women 
with one to three positive lymph nodes. A previous Early 
Breast Cancer Trialists’ Collaborative Group (EBCTCG) 
analysis of individual patient data from randomised trials 
of postmastectomy radiotherapy7 did not give detailed 
results for women who had one to three positive lymph 
nodes after axillary dissection to at least level II, nor did it 
distinguish between trials in which radiotherapy 
included the chest wall and the regional lymph nodes 
and other trials in which radiotherapy was given only to 
the regional lymph nodes. For the present report, 
additional data regarding the extent of axillary dissection 
and regarding the number of positive lymph nodes have 
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been obtained and reviewed for each woman, and we 
present detailed results according to these factors for 
trials that included radiotherapy to the chest wall, as is 
usual in current practice.
Methods
Study design
Trials beginning before 2000 of adjuvant radiotherapy 
versus no radiotherapy but the same surgery after 
mastectomy for invasive cancer were eligible for 
inclusion in our meta-analysis of individual patient data. 
Trial identiﬁ cation and data handling were as previously 
reported.7 For every woman, information was sought 
about initial patient and tumour characteristics, allocated 
treatment, time to ﬁ rst recurrence, whether the ﬁ rst 
recurrence was locoregional or distant, and date last 
known alive or date and underlying cause of death. 
When no recurrence was reported before breast cancer 
death, distant recurrence was assumed to have just 
preceded it. If contralateral breast cancer occurred 
before any other recurrence, follow-up was censored on 
that date in analyses of recurrence. Information about 
the extent of axillary surgery was reviewed. Women were 
classiﬁ ed as having axillary dissection if they were in a 
trial in which the protocol required removal of axillary 
lymph nodes in at least levels I and II. For the few trials 
in which the extent of axillary dissection was not 
described in terms of levels, women were classiﬁ ed as 
having axillary dissection if the trial protocol or 
publications indicated that the median number of 
resected nodes was at least ten or, if individual 
information was available,8–11 at least ten nodes had been 
resected. Women with less extensive axillary surgery 
were classiﬁ ed as having axillary sampling.
Statistical analysis
As in the recent overview of radiotherapy after breast-
conserving surgery,12 the main emphasis in analyses of 
recurrence was on overall recurrence (ie, any ﬁ rst 
recurrence, irrespective of whether locoregional or 
distant), although observed risks of locoregional 
Women Deaths Woman-years since diagnosis* Women given systemic 
therapy† (%)
Median 
per 
woman
Total 
(×10³)
Distribution by 
years (×10³)
Chemo-
therapy
Tamox-
ifen and 
ER+‡
Any
<10 10–19 ≥20
(A) Axillary dissection
pN0 700 480 20·1 13·5 6·1 4·4 3·0 22% 27% 47%
pN+ 3131 2074 7·2 30·1 20·3 7·9 1·9 75% 22% 91%
pN1–3 1314 759 12·3 17·3 10·3 5·3 1·6 65% 24% 86%
pN4+ 1772 1286 4·8 12·4 9·7 2·5 0·3 81% 21% 95%
pN?+ 45 29 6·7 0·4 0·3 0·1 <0·1 100% 0% 100%
pN unknown 56 39 10·6 0·7 0·4 0·2 0·1 29% 71% 98%
Total 3887 2593 9·0 44·3 26·8 12·5 4·9 64% 24% 83%
(B) Axillary sampling
pN0 870 595 17·6 15·4 7·5 5·1 2·8 10% 11% 21%
pN+ 2541 1689 7·8 24·2 17·0 6·4 0·2 56% 28% 84%
pN unknown 654 460 9·3 7·1 4·6 2·1 0·4 44% 30% 74%
Total 4065 2744 9·8 46·8 29·1 13·7 4·0 44% 25% 69%
(C) Axillary surgery, but extent unknown
pN0 24 12 8·5 0·2 0·2 <0·1 ·· 100% 0% 100%
pN+ 149 69 11·5 1·3 1·1 0·2 ·· 100% 0% 100%
pN unknown 10 6 11·0 0·1 0·1 <0·1 ·· 100% 0% 100%
Total 183 87 10·1 1·6 1·4 0·2 ·· 100% 0% 100%
Total 
(A)+(B)+(C)
8135 5424 9·4 92·7 57·3 26·4 9·0 55% 24% 77%
Data were available for 22 trials, start dates 1964–86, and were unavailable for four trials including about 400 women. 
In all 22 trials for which data were available, radiotherapy was given to the chest wall and the supraclavicular or the 
axillary fossa (or both). In 20 of these 22 trials it was also given to the internal mammary chain. Details of the 
treatments given in these 22 trials are in appendix pp 10–12. Details of other trials of radiotherapy in combination with 
mastectomy are in appendix pp 52–53, 64–65, 70–71, 78–79. pN0=pathologically node-negative. pN+=pathologically 
node-positive. pN1–3=one to three pathologically positive nodes. pN4+=at least four pathologically positive nodes. 
pN?+=known to be pN+, but not whether pN1–3 or pN4+. pN unknown=pathological nodal status unknown. 
*Numbers of woman-years of follow-up for mortality; many trials followed up women for only 10 years for recurrence. 
†Chemotherapy was usually cyclophosphamide, methotrexate, and ﬂ uorouracil (CMF); only 3% of women were 
classiﬁ ed as oestrogen-receptor positive (ER+) and were in trials where both tamoxifen and chemotherapy were given. 
‡Oestrogen-receptor positive.
 Table: Availability of data from randomised trials beginning before the year 2000 and comparing 
radiotherapy to the chest wall and regional nodes after mastectomy and axillary surgery versus no 
radiotherapy but the same surgery
Figure 1: Trials included in analysis
31 747 records identiﬁed through database 
 searching or other means; abstracts 
 read when available, otherwise 
 titles only
18 340 records excluded
13 407 papers obtained and read
8520 papers excluded
4887 trial reports ﬁled and assessed for 
 eligibility
4861 trial reports excluded
26 eligible trials identiﬁed
22 trials with data available for 
 8135 women included in 
 quantitative synthesis 
 (meta-analysis), so individual 
 patient data obtained for around 
 95% of eligible women
4 trials with individual patient 
 data unavailable (around 
 400 women)
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recurrence as a ﬁ rst event are also presented. All 
recurrence analyses present data only to year 10, because 
many trials did not follow women beyond this time for 
recurrence. Analyses of mortality present data to year 20. 
Deaths of unknown cause before recurrence were 
assumed to be from causes other than breast cancer, 
because most occurred many years after trial entry, by 
which time non-breast-cancer mortality predominated. 
Most other aspects of the statistical methods were as 
previously described,7 but further information is given 
in the appendix pp 7–9. Person-years up to Jan 1, 2009, 
were included. Analyses were stratiﬁ ed by trial, 
individual follow-up year, age at entry (<40, 40–49, 50–59, 
60–69, or ≥70 years), and pathological nodal status 
(node-negative disease, one to three positive nodes, four 
or more positive nodes, node-positive disease with 
unknown number of nodes aﬀ ected, or nodal status 
unknown). Analyses were programmed in the statistical 
package Stata (version 12.1) and the programming 
language R (version 2.13.2).
Role of the funding sources
The Secretariat had full access to all data and analyses. 
The funding agencies had no role in data collection, 
analysis, interpretation, or reporting. A preliminary 
manuscript was presented to collaborators in October, 
2013, and then revised on the basis of their comments. 
SD, CT, and PMcG had responsibility for submission of 
the report for publication.
Results
Information was available for 8135 women in 22 trials in 
which radiotherapy included the chest wall and regional 
lymph nodes (table; ﬁ gure 1). Median length of follow-up 
was 9·4 years per woman (IQR 3·7–17·3) and 5424 women 
(67%) were known to have died. The extent of axillary 
surgery was known for all but 183 (2%) women. 
1594 (20%) women had pathologically node-negative 
disease, 5821 (72%) had pathologically node-positive 
disease, and for 720 pathological nodal status was 
unknown. There were 3831 women for whom pathological 
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Figure 2: Eﬀ ect of radiotherapy (RT) after mastectomy and axillary dissection (Mast+AD) on 10-year risks of locoregional and overall recurrence and on 
20-year risk of breast cancer mortality in 700 women with pathologically node-negative (pN0) disease and in 3131 women with pathologically 
node-positive (pN+) disease
Analyses of locoregional recurrence ﬁ rst ignore distant recurrences, see appendix pp 8–9 for details. See appendix pp 14, 16, for analyses of both locoregional 
and distant recurrences, and appendix pp 13, 15, for analyses of overall mortality. RR=rate ratio. NS=not signiﬁ cant. Vertical lines indicate 1 SE above or below 
the 5, 10, 15, and 20 year percentages.
Articles
2130 www.thelancet.com   Vol 383   June 21, 2014
nodal status was known and who were classiﬁ ed as 
having axillary dissection (however, for 45 women with 
node-positive disease, the number of nodes aﬀ ected was 
not known); all of these women were in trials in which 
radiotherapy included the chest wall, the supraclavicular 
or axillary fossa (or both), and the internal mammary 
chain (appendix pp 10–12).
Of the 1594 women with node-negative disease, 
700 (44%) had axillary dissection, 870 (55%) had axillary 
sampling, and for 24 (1%) the extent of axillary surgery 
was unknown. For the 700 women who had axillary 
dissection, only 1·4% of unirradiated women had a 
locoregional recurrence before a distant recurrence 
(appendix p 14), and radiotherapy had no signiﬁ cant eﬀ ect 
on locoregional recurrence (2p>0·1), overall recurrence 
(rate ratio [RR], irradiated vs not,  1·06, 95% CI 0·76–1·48, 
2p>0·1), or breast cancer mortality (RR 1·18, 
95% CI 0·89–1·55, 2p>0·1; ﬁ gure 2A–C). Radiotherapy 
did, however, increase overall mortality (RR 1·23, 
95% CI 1·02–1·49, 2p=0·03; appendix p 13). By contrast, 
for the 870 women with node-negative disease who had 
only axillary sampling, 16·3% of unirradiated women had 
a locoregional recurrence before any distant recurrence 
(appendix p 37), and radiotherapy reduced locoregional 
recurrence (2p<0·00001) and overall recurrence (RR 0·61, 
95% CI 0·47–0·80, 2p=0·0003), but had no signiﬁ cant 
eﬀ ect either on breast cancer mortality (RR 0·97, 
95% CI 0·77–1·22, 2p>0·1) or on overall mortality 
(RR 1·00, 95% CI 0·84–1·18, 2p>0·1; appendix p 36).
Of the 5821 women with node-positive disease, 
3131 (54%) had axillary dissection, 2541 (44%) had axillary 
sampling, and for 149 (2%) the extent of axillary surgery 
was unknown. Radiotherapy reduced locoregional 
recurrence and overall recurrence both for women who 
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Figure 3: Eﬀ ect of radiotherapy (RT) after mastectomy and axillary dissection (Mast+AD) on 10-year risks of locoregional and overall recurrence and on 
20-year risk of breast cancer mortality in 1314 women with one to three pathologically positive nodes (pN1–3) and in 1772 women with four or more 
pathologically positive nodes (pN4+)
Analyses of locoregional recurrence ﬁ rst ignore distant recurrences, see appendix pp 8–9 for details. See appendix pp 19, 28, for analyses of both locoregional 
and distant recurrences, and appendix pp 18, 27, for analyses of overall mortality. RR=rate ratio. NS=not signiﬁ cant. Vertical lines indicate 1 SE above or below the 
5, 10, 15, and 20 year percentages.
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had axillary dissection and for women who had axillary 
sampling (2p<0·00001 for all four comparisons). 
However, 29·0% of the unirradiated women with axillary 
sampling had a locoregional recurrence before any 
distant recurrence (appendix p 39) compared with only 
19·4% of the unirradiated women who had axillary 
dissection (appendix p 16) and the proportional reduction 
in the rate of overall recurrence was larger after axillary 
sampling (RR 0·59, 95% CI 0·53–0·66; appendix p 38) 
than after axillary dissection (RR 0·75, 95% CI 0·67–0·83, 
ﬁ gure 2E; 2p for diﬀ erence between RRs, 0·003).
For the 3131 women with node-positive disease who 
had axillary dissection, the proportional reductions in the 
overall recurrence rates did not diﬀ er signiﬁ cantly 
between years 0–4 and 5–9 (appendix p 17). Overall 
recurrence rates in the absence of radiotherapy were, 
however, higher during years 0–4 than during years 5–9 
(ﬁ gure 2E). Consequently, the absolute reduction with 
radiotherapy in the 10-year overall recurrence risk 
(10·6%—ie, 62·5% vs 51·9%), was only slightly greater 
than the 5-year absolute reduction (9·4%—ie, 52·4% vs 
43·0%). The proportional reduction in the overall 
recurrence rate with radiotherapy did not diﬀ er according 
to whether or not there was a trial policy of giving 
systemic therapy (ie, either chemotherapy or, for 
oestrogen-receptor positive women, tamoxifen), or with 
any other known factor. For these 3131 women, 
radiotherapy reduced breast cancer mortality (RR 0·84, 
95% CI 0·76–0·94, 2p=0·001). There was no signiﬁ cant 
heterogeneity in the proportional reduction in the breast 
cancer mortality rate according to any known tumour-
related or treatment-related factor. There appeared to be 
little eﬀ ect of radiotherapy on breast cancer mortality in 
the ﬁ rst few years, but after that the breast cancer 
mortality rate was lower in the radiotherapy group than 
in the controls until years 10–15 and possibly beyond 
(appendix p 17). Radiotherapy also reduced overall 
mortality in these 3131 women with node-positive disease 
who had axillary dissection (RR 0·89, 95% CI 0·81–0·97, 
2p=0·01; appendix p 15).
Among the 1314 women who had axillary dissection 
and only one to three positive nodes, radiotherapy 
reduced locoregional recurrence (2p<0·00001), overall 
recurrence (RR 0·68, 95% CI 0·57–0·82, 2p=0·00006), 
and breast cancer mortality (RR 0·80, 95% CI 0·67–0·95, 
2p=0·01; ﬁ gure 3A–C). 813 women (62%) were in trials 
in which the policy regarding systemic therapy for both 
randomised groups was to give only chemotherapy, 
Category
Category
Rate ratio (SE)Ratio of annual event rates
       RT : no RTAllocated
RT
Allocated
no RT
No systemic therapy
Chemotherapy and/or ER+tam+
Diﬀerence between treatment eﬀects in two categories: χ21=0·4; 2p>0·1, NS
 34/93
 (36·6%)
 42/88
 (47·7%)
 –4·1  16·8
 177/539
 (32·8%)
 262/594
 (44·1%)
 –38·2  94·5
 211/
 632
 (33·4%)
 304/
 682
 (44·6%)
 –42·3  111·4 0·68 (SE 0·08)
2p=0·00006
 0·79 (SE 0·22)
 0·67 (SE 0·08)
95% 95% CI
95% 95% CI
1·00 2·01·50·5
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Log-rank
O–E
Variance
of O–E
RT events
Total
A Any first recurrence (years 0–9)
Rate ratio (SE)Ratio of annual death rates
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no RT
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Chemotherapy and/or ER+tam+
Diﬀerence between treatment eﬀects in two categories: χ21=0·4; 2p>0·1, NS
 46/93
 (49·5%)
 52/88
 (59·1%)
 –2·1  21·8
 202/539
 (37·5%)
 273/594
 (46·0%)
 –25·9  103·7
 248/
 632
 (39·2%)
325/
 682
 (47·7%)
 –28·0  125·5 0·80 (SE 0·08)
2p=0·01
 0·91 (SE 0·20)
 0·78 (SE 0·09)
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of O–E
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Figure 4: Eﬀ ect of radiotherapy (RT) after mastectomy and axillary dissection on overall recurrence during years 0–9 and on breast cancer mortality for the 
entire follow-up in 1314 women with one to three pathologically positive nodes, according to whether or not they were in trials in which systemic therapy 
was given to both randomised treatment groups
Chemotherapy was usually cyclophosphamide, methotrexate, and ﬂ uorouracil. ER-negative women in trials in which tamoxifen was given to both groups are 
included in the “no systemic” category. ER=oestrogen receptor. tam=tamoxifen. NS=not signiﬁ cant. SE=standard error.
Articles
2132 www.thelancet.com   Vol 383   June 21, 2014
274 (21%) had oestrogen-receptor positive disease and 
were in trials in which the policy was only to give 
tamoxifen, 46 (3%) had oestrogen-receptor positive 
disease and were in trials in which the policy was to give 
both tamoxifen and chemotherapy, and 181 (14%) were 
in trials in which the policy was not to give systemic 
therapy. The proportional reductions in the rates of 
overall recurrence and of breast cancer mortality did not 
diﬀ er signiﬁ cantly according to whether or not systemic 
therapy was given (ﬁ gure 4) or according to any other 
known tumour-related or treatment-related factor 
(appendix p 20). When we considered separately the 
1133 women with one to three positive nodes after 
axillary dissection who were in trials in which the policy 
was to give systemic therapy, radiotherapy reduced the 
rates of overall recurrence by a third (RR 0·67, 
95% CI 0·55–0·82, 2p=0·00009) and breast cancer 
mortality by slightly more than a ﬁ fth (RR 0·78, 
95% CI 0·64–0·94, 2p=0·01; ﬁ gure 5).
For 683 of these 1133 women, additional information 
about the number of positive nodes was available. 
318 women had only one positive node, of whom 145 
were randomly assigned to receive radiotherapy and 173 
were randomly assigned not to receive it. 17·8% of the 
173 unirradiated women with one positive node had a 
locoregional recurrence before any distant recurrence 
compared with only 2·3% of the irradiated women 
(2p<0·00001; appendix p 24), and radiotherapy reduced 
the rate of overall recurrence (0·60, 95% CI 0·39–0·92, 
2p=0·02; ﬁ gure 6A). This proportional reduction did not 
diﬀ er signiﬁ cantly from the corresponding reduction for 
the 365 women with two to three positive nodes after 
axillary dissection and who received systemic therapy (2p 
for diﬀ erence >0·10). Likewise the proportional reduction 
in breast cancer mortality did not diﬀ er signiﬁ cantly 
according to the number of positive nodes (ﬁ gure 6B).
For the 1772 women who had four or more positive 
nodes after axillary dissection, radiotherapy reduced 
locoregional recurrence (2p<0·00001) and overall recur-
rence (RR 0·79, 95% CI 0·69–0·90, 2p=0·0003) and 
breast cancer mortality (RR 0·87, 95% CI 0·77–0·99, 
2p=0·04; ﬁ gure 3D–F). 1677 (95%) of these women 
received systemic therapy and among them the 
proportional reductions in the overall recurrence and 
breast cancer mortality rates with radiotherapy did not 
diﬀ er signiﬁ cantly from those for the few who did not (2p 
for all diﬀ erences >0·1; appendix p 29). Additional 
information about the number of positive nodes was 
available for 973 of the 1772 women with four or more 
positive nodes after axillary dissection. There were no 
signiﬁ cant diﬀ erences in the proportional reductions 
with radiotherapy in the rates of overall recurrence or 
breast cancer mortality between the 542 women with 
four to nine positive nodes and the 431 women with ten 
or more positive nodes (2p>0·1 for all diﬀ erences). 
Further information about women with four or more 
positive lymph nodes is given in appendix pp 27–35.
Information was also available from several other trials 
of postmastectomy radiotherapy. In eight trials (see 
appendix pp 52–53 for references) in which axillary 
surgery was performed and radiotherapy was given to the 
regional nodes but not to the chest wall, a total of 
2304 women were randomised and the median follow-up 
was 7·2 years per woman (IQR 3·4–16·5; appendix 
pp 52–63). Pathological nodal status was available for 
1494 women. Among the 1029 women with node-positive 
disease, 20·9% of unirradiated women had a locoregional 
recurrence before any distant recurrence compared with 
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to both randomised treatment groups
Analyses of locoregional recurrence ﬁ rst ignore distant recurrences, see appendix pp 8–9 for details. See appendix p 22 for analyses of both locoregional and distant 
recurrences, and appendix p 21 for analyses of overall mortality. RR=rate ratio. Vertical lines indicate 1 SE above or below the 5, 10, 15, and 20 year percentages.
Articles
www.thelancet.com   Vol 383   June 21, 2014 2133
only 6·8% of irradiated women (2p<0·00001; 
appendix p 57) but radiotherapy had no signiﬁ cant eﬀ ect 
on overall recurrence (RR 0·88, 95% CI 0·73–1·06, 
2p>0·1), and no eﬀ ect at all on the rate of breast cancer 
mortality (RR 1·00, 95% CI 0·82–1·20, 2p>0·1; appendix 
p 56). Information about further categories of trials of 
radiotherapy in combination with mastectomy is 
presented in appendix pp 64–85.
Discussion
Previous meta-analyses have shown that, for women 
with node-positive disease, postmastectomy radiotherapy 
reduced the risks of both recurrence and breast cancer 
mortality.7 There has, however, been much debate as to 
whether this beneﬁ t was seen only because some women 
had limited axillary surgery. To investigate this issue, we 
reviewed all available evidence regarding the extent of 
axillary surgery for the women in these trials, including 
trial protocols, publications, and individual patient 
information if it was available. Additionally, we included 
the longer follow-up now available for many trials. The 
revised analyses of these updated data show that in these 
women who had mastectomy and axillary dissection of at 
least levels I and II, radiotherapy that included the chest 
wall, the supraclavicular or axillary fossa (or both), and 
the internal mammary chain reduced recurrence, breast 
cancer mortality, and overall mortality for all node-
positive women considered together. When women with 
one to three and four or more involved axillary nodes 
were considered separately, the beneﬁ ts of 
postmastectomy radiotherapy were clearly seen in each 
group. In these trials, 90% of women with one to three 
positive nodes and 95% of women with four or more 
positive nodes received some form of systemic treatment 
for their breast cancer. The most common chemotherapy 
was cyclophosphamide, methotrexate, and ﬂ uorouracil 
and the most common endocrine therapy was tamoxifen. 
The beneﬁ cial eﬀ ects of radiotherapy on recurrence and 
breast cancer mortality remained apparent when women 
with one to three involved lymph nodes who were in 
trials in which the policy was to give systemic therapy 
were considered on their own. By contrast, in women 
with node-negative disease who received mastectomy 
and axillary dissection, among whom the proportion of 
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women who had a locoregional recurrence before any 
distant recurrence was small, there was no evidence that 
radiotherapy provided any beneﬁ t. Non-breast-cancer 
mortality and the incidence of contralateral and other 
second cancers in these and other trials of radiotherapy 
in early breast cancer will be reported elsewhere.
There have been substantial changes in practice since 
these women were treated. For example, breast screening 
has improved and local therapies are more targeted. Also, 
the accuracy of lymph-node analysis has increased, with 
more frequent use of serial sectioning and more frequent 
recognition of micrometastases. Hence, some of the 
women who were classiﬁ ed as having node-negative 
disease in these trials might have been found to be node-
positive if they had been assessed today.13,14 Furthermore, 
many women now receive better systemic therapy that is 
more eﬀ ective at treating both local and distant disease.15,16 
Therefore the absolute risk of a recurrence is likely to be 
lower for women being considered for postmastectomy 
radiotherapy today than for the women in these trials and 
the absolute risk reductions achieved with radiotherapy 
are also likely to be smaller.
The proportional risk reductions we observed could be 
applied to women today with one to three positive nodes 
if they have appreciable risks of recurrence in the absence 
of radiotherapy and they might be the best guide that is 
currently available to help to estimate the likely absolute 
beneﬁ ts from radiotherapy for women today. For 
example, for cancer recurrence, the unirradiated women 
in these trials with one to three positive nodes had an 
absolute 10-year risk of overall recurrence of 45·7%, 
which was reduced to 34·2% by their radiotherapy, so 
their absolute gain was 11·5%. If the absolute 10-year risk 
of overall recurrence for women being considered for 
postmastectomy radiotherapy today were about half of 
this (ie, 23%), then the absolute gain might also be 
roughly halved (ie, to around 6%). Similarly, if the 20-year 
risk of breast cancer mortality in women with one to 
three positive nodes were roughly halved for women 
today, the absolute gain from radiotherapy would also be 
roughly halved from 7·9% to around 4%.
The proportional gains from radiotherapy might, 
however, be greater for women irradiated today than 
suggested by this example, because radiotherapy 
planning has changed substantially and women today 
receive better coverage of target areas. Furthermore, 
doses to normal tissues are lower today, so the risks of 
radiotherapy are also likely to be lower.
The most common site of locoregional cancer 
recurrence after mastectomy is the chest wall.8,17 Eight 
trials have been carried out, including around 
2000 women, in which the chest wall was not irradiated. 
In these eight trials radiotherapy reduced locoregional 
recurrence in women with pathologically node-positive 
disease but had no signiﬁ cant eﬀ ect on overall recurrence 
and no eﬀ ect at all on breast cancer mortality. This 
ﬁ nding suggests that the chest wall is an important target 
in postmastectomy radiotherapy. Direct evidence 
regarding the eﬀ ect of radiotherapy to the chest wall is 
being collected,18 but mature results from this current 
trial will not be available for some time. In the trials that 
are the main focus of the present report the chest wall, 
the supraclavicular or the axillary fossa (or both), and the 
internal mammary chain were all irradiated. Which 
regional lymph nodes should be irradiated after 
mastectomy is currently uncertain. Other randomised 
trials are investigating the risks and beneﬁ ts of regional 
node irradiation in addition to chest wall or whole breast 
radiotherapy,19–21 but again long-term results of these 
trials are not yet available.
In circumstances in which, even without radiotherapy, 
only a small percentage of women have locoregional 
recurrence as a ﬁ rst event after mastectomy, radiotherapy 
is unlikely to reduce either overall recurrence or breast 
cancer mortality. This scenario is illustrated by the 
women in these 22 trials who had axillary dissection and 
node-negative disease. If, however, a substantial 
percentage of women have locoregional recurrence as a 
ﬁ rst event in the absence of radiotherapy, then 
radiotherapy is likely to provide beneﬁ t both by preventing 
locoregional recurrence and by reducing distant recur-
rence and breast cancer mortality. This situation is 
illustrated by the 3131 women in these 22 trials who had 
axillary dissection and node-positive disease, for whom 
radiotherapy reduced the 10-year risk of a recurrence of 
any type by 10·6% (62·5% vs 51·9%) and the 20-year risk 
of death from breast cancer by 8·1% (66·4% vs 58·3%). 
We previously reported that in the trials of radiotherapy 
after breast-conserving surgery, the ﬁ ndings for both 
node-negative and node-positive disease were consistent 
with about one breast cancer death being avoided in the 
ﬁ rst 15 years after radiotherapy for every four recurrences 
of any type (ie, either loco regional or distant) avoided in 
the 10 years after radiotherapy.12 The women with node-
positive disease in the 22 trials reported here generally 
had more advanced cancers and more extensive 
radiotherapy than the women in the trials of radiotherapy 
after breast-conserving surgery and, for these women, 
about one breast cancer death was avoided in the 20 years 
after radiotherapy for every 1·5 recurrences of any type 
(ie, either locoregional or distant) avoided during the ﬁ rst 
10 years after radiotherapy.
Breast cancer is a disease with a long natural history. 
Many of the women in these trials have now been 
followed up for 20 years and therefore they provide 
information about the long-term beneﬁ ts of radiotherapy. 
Radiotherapy techniques have improved in the past few 
decades and so the proportional beneﬁ ts of radiotherapy 
are likely to be larger than in these trials. However, the 
absolute risks of breast cancer recurrence and mortality 
have reduced in many countries because of advances in 
detection and treatment of breast cancer, so the absolute 
beneﬁ ts from postmastectomy radiotherapy today are 
likely to be smaller than those reported here.
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